146 related articles for article (PubMed ID: 29662190)
21. Human ovarian-carcinoma cell lines express IL-4 and IL-13 receptors: comparison between IL-4- and IL-13-induced signal transduction.
Murata T; Obiri NI; Puri RK
Int J Cancer; 1997 Jan; 70(2):230-40. PubMed ID: 9009165
[TBL] [Abstract][Full Text] [Related]
22. Erlotinib or gefitinib for the treatment of relapsed platinum pretreated non-small cell lung cancer and ovarian cancer: a systematic review.
Murphy M; Stordal B
Drug Resist Updat; 2011 Jun; 14(3):177-90. PubMed ID: 21435938
[TBL] [Abstract][Full Text] [Related]
23. Apigetrin inhibits gastric cancer progression through inducing apoptosis and regulating ROS-modulated STAT3/JAK2 pathway.
Sun Q; Lu NN; Feng L
Biochem Biophys Res Commun; 2018 Mar; 498(1):164-170. PubMed ID: 29408335
[TBL] [Abstract][Full Text] [Related]
24. Combination of paclitaxel, bevacizumab and MEK162 in second line treatment in platinum-relapsing patient derived ovarian cancer xenografts.
Ricci F; Guffanti F; Damia G; Broggini M
Mol Cancer; 2017 May; 16(1):97. PubMed ID: 28558767
[TBL] [Abstract][Full Text] [Related]
25. A Novel Platinum-Maurocalcine Conjugate Induces Apoptosis of Human Glioblastoma Cells by Acting through the ROS-ERK/AKT-p53 Pathway.
Aroui S; Dardevet L; Ben Ajmia W; de Boisvilliers M; Perrin F; Laajimi A; Boumendjel A; Kenani A; Muller JM; De Waard M
Mol Pharm; 2015 Dec; 12(12):4336-48. PubMed ID: 26465677
[TBL] [Abstract][Full Text] [Related]
26. [Effects of Zengmian Yiliu Recipe combined cisplatin on the tumor inhibition rate in platinum-resistant ovarian cancer].
Qi C; Zhang QH; Li JX
Zhongguo Zhong Xi Yi Jie He Za Zhi; 2012 Jun; 32(6):817-21. PubMed ID: 22978111
[TBL] [Abstract][Full Text] [Related]
27. Blockade of PDGFRβ circumvents resistance to MEK-JAK inhibition via intratumoral CD8
Kalimutho M; Sinha D; Mittal D; Srihari S; Nanayakkara D; Shafique S; Raninga P; Nag P; Parsons K; Khanna KK
J Exp Clin Cancer Res; 2019 Feb; 38(1):85. PubMed ID: 30777101
[TBL] [Abstract][Full Text] [Related]
28. Topoisomerase inhibitors promote cancer cell motility via ROS-mediated activation of JAK2-STAT1-CXCL1 pathway.
Liu J; Qu L; Meng L; Shou C
J Exp Clin Cancer Res; 2019 Aug; 38(1):370. PubMed ID: 31438997
[TBL] [Abstract][Full Text] [Related]
29. Isoliquiritigenin inhibits the proliferation of human renal carcinoma Caki cells through the ROS-mediated regulation of the Jak2/STAT3 pathway.
Kim DH; Park JE; Chae IG; Park G; Lee S; Chun KS
Oncol Rep; 2017 Jul; 38(1):575-583. PubMed ID: 28560439
[TBL] [Abstract][Full Text] [Related]
30. Mechanistic Nanotherapeutic Approach Based on siRNA-Mediated DJ-1 Protein Suppression for Platinum-Resistant Ovarian Cancer.
Schumann C; Chan S; Khalimonchuk O; Khal S; Moskal V; Shah V; Alani AW; Taratula O; Taratula O
Mol Pharm; 2016 Jun; 13(6):2070-83. PubMed ID: 27170529
[TBL] [Abstract][Full Text] [Related]
31. [Effects of Yisui Jiedu Recipe on JAK2-STAT5 signal transduction pathway in bone marrow hematopoietic cells from patients with myelodysplastic syndrome-refractory anemia].
Tian SL; Zhou YM; Huang T; Xue ZZ; He W
Zhong Xi Yi Jie He Xue Bao; 2008 Feb; 6(2):185-9. PubMed ID: 18241656
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of JAK2/STAT3 and activation of caspase‑9/3 are involved in KYS05090S‑induced apoptosis in ovarian cancer cells.
Kim BI; Kim JH; Sim DY; Nam M; Jung JH; Shim B; Lee J; Kim SH
Int J Oncol; 2019 Jul; 55(1):203-210. PubMed ID: 31059018
[TBL] [Abstract][Full Text] [Related]
33. [Chemotherapy resistance induced by interleukin-6 in ovarian cancer cells and its signal transduction pathways].
Wang Y; Li LZ; Ye L; Niu XL; Liu X; Zhu YQ; Sun WJ; Liang YJ
Zhonghua Fu Chan Ke Za Zhi; 2010 Sep; 45(9):691-8. PubMed ID: 21092551
[TBL] [Abstract][Full Text] [Related]
34. The role of topotecan for extending the platinum-free interval in recurrent ovarian cancer: an in vitro model.
Horowitz NS; Hua J; Gibb RK; Mutch DG; Herzog TJ
Gynecol Oncol; 2004 Jul; 94(1):67-73. PubMed ID: 15262121
[TBL] [Abstract][Full Text] [Related]
35. Critical role of FANCC in JAK2 V617F mutant-induced resistance to DNA cross-linking drugs.
Ueda F; Sumi K; Tago K; Kasahara T; Funakoshi-Tago M
Cell Signal; 2013 Nov; 25(11):2115-24. PubMed ID: 23838005
[TBL] [Abstract][Full Text] [Related]
36. CAFs enhance paclitaxel resistance by inducing EMT through the IL‑6/JAK2/STAT3 pathway.
Wang L; Zhang F; Cui JY; Chen L; Chen YT; Liu BW
Oncol Rep; 2018 May; 39(5):2081-2090. PubMed ID: 29565447
[TBL] [Abstract][Full Text] [Related]
37. ABT737 reverses cisplatin resistance by targeting glucose metabolism of human ovarian cancer cells.
Xu Y; Gao W; Zhang Y; Wu S; Liu Y; Deng X; Xie L; Yang J; Yu H; Su J; Sun L
Int J Oncol; 2018 Sep; 53(3):1055-1068. PubMed ID: 30015875
[TBL] [Abstract][Full Text] [Related]
38. NADPH oxidase promotes pancreatic cancer cell survival via inhibiting JAK2 dephosphorylation by tyrosine phosphatases.
Lee JK; Edderkaoui M; Truong P; Ohno I; Jang KT; Berti A; Pandol SJ; Gukovskaya AS
Gastroenterology; 2007 Nov; 133(5):1637-48. PubMed ID: 17983808
[TBL] [Abstract][Full Text] [Related]
39. JAK2 regulation by licochalcone H inhibits the cell growth and induces apoptosis in oral squamous cell carcinoma.
Oh HN; Oh KB; Lee MH; Seo JH; Kim E; Yoon G; Cho SS; Cho YS; Choi HW; Chae JI; Shim JH
Phytomedicine; 2019 Jan; 52():60-69. PubMed ID: 30599913
[TBL] [Abstract][Full Text] [Related]
40. Overexpression of Tyro3 receptor tyrosine kinase leads to the acquisition of taxol resistance in ovarian cancer cells.
Lee C
Mol Med Rep; 2015 Jul; 12(1):1485-92. PubMed ID: 25815442
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
